[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602005024021D1 - GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA - Google Patents

GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA

Info

Publication number
DE602005024021D1
DE602005024021D1 DE602005024021T DE602005024021T DE602005024021D1 DE 602005024021 D1 DE602005024021 D1 DE 602005024021D1 DE 602005024021 T DE602005024021 T DE 602005024021T DE 602005024021 T DE602005024021 T DE 602005024021T DE 602005024021 D1 DE602005024021 D1 DE 602005024021D1
Authority
DE
Germany
Prior art keywords
cancer
anln
rhoa
interaction
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005024021T
Other languages
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of DE602005024021D1 publication Critical patent/DE602005024021D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602005024021T 2004-08-10 2005-08-09 GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA Active DE602005024021D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60056104P 2004-08-10 2004-08-10
PCT/JP2005/014887 WO2006016697A1 (en) 2004-08-10 2005-08-09 Non-small cell lung cancer-related gene, anln, and its interactions with rhoa

Publications (1)

Publication Number Publication Date
DE602005024021D1 true DE602005024021D1 (de) 2010-11-18

Family

ID=35355888

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024021T Active DE602005024021D1 (de) 2004-08-10 2005-08-09 GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA

Country Status (6)

Country Link
US (1) US20090297500A1 (de)
EP (1) EP1787122B1 (de)
JP (1) JP4874234B2 (de)
AT (1) ATE483979T1 (de)
DE (1) DE602005024021D1 (de)
WO (1) WO2006016697A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8131476B2 (en) 2006-08-07 2012-03-06 General Electric Company System and method for co-registering multi-channel images of a tissue micro array
US8060348B2 (en) 2006-08-07 2011-11-15 General Electric Company Systems for analyzing tissue samples
WO2008063413A2 (en) 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
US20100184047A1 (en) * 2007-03-30 2010-07-22 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting the cdca8-aurkb complex
EP2161577A1 (de) * 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN-Protein
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
US20120053253A1 (en) * 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
BR112012032537B8 (pt) 2010-07-09 2022-10-18 Somalogic Inc Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
JP6127972B2 (ja) 2011-09-09 2017-05-17 コニカミノルタ株式会社 組織染色方法
SG11201400375SA (en) * 2011-10-24 2014-04-28 Somalogic Inc Lung cancer biomarkers and uses thereof
JP5806168B2 (ja) * 2012-06-19 2015-11-10 国立大学法人 岡山大学 抗浸潤薬の新規スクリーニング法
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
EP3143160B1 (de) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gensignaturen für krebsprognosen
US10870854B2 (en) 2016-06-09 2020-12-22 The Board Of Regents Of The University Of Texas System Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2004091548A2 (en) * 2003-04-15 2004-10-28 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods

Also Published As

Publication number Publication date
EP1787122A1 (de) 2007-05-23
WO2006016697A1 (en) 2006-02-16
JP4874234B2 (ja) 2012-02-15
ATE483979T1 (de) 2010-10-15
EP1787122B1 (de) 2010-10-06
US20090297500A1 (en) 2009-12-03
JP2008510126A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
DE602005024021D1 (de) GEN ANLN IN VERBINDUNG MIT NICHT-KLEINZELLIGEM LUNGENKREBS UND SEINE WECHSELWIRKUNGEN MIT RhoA
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
CY1118612T1 (el) Μεθοδοι και χημικες συνθεσεις για την θεραπευτικη αντιμετωπιση των εμμενουσων λοιμωξεων και του καρκινου μεσω αναστολης της οδου προγραμματισμενου κυτταρικου θανατου 1 (pd-1)
WO2009049214A3 (en) Inhibition and treatment of prostate cancer metastasis
TW200716141A (en) Compositions and methods for treatment for neoplasms
ATE422162T1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
PT1893196E (pt) Composto de diaril-hidantoína
WO2007053573A3 (en) Treatment of cancer with sorafenib
TW200600785A (en) Method for diagnosing non-small cell lung cancer
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
EP2298304A3 (de) Zur Krebsbehandlung nützliche Carbolinderivate
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
ATE393240T1 (de) Verfahren zum nachweis von prostatakrebs
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
DK1951759T3 (da) Anti-EGFR-antistoffer
MX2007006640A (es) Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
WO2010042933A3 (en) Inhibition and treatment of prostate cancer metastasis
WO2006086772A3 (en) DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS
MX2018000598A (es) Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.
DE602005026962D1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
WO2023004342A3 (en) Methods for identifying adar1 inhibitors, and compositions and methods of use in treating cancer
TW200605885A (en) Multicyclic lonidamine analogs